Clinical Research Papers:
Comparison of biological target volume metrics based on FDG PET-CT and 4DCT for primary non-small-cell lung cancer
PDF | HTML | How to cite
Metrics: PDF 1081 views | HTML 1869 views | ?
Yingjie Zhang1,2, Jianbin Li1,2, Yili Duan3, Wei Wang1,2, Fengxiang Li1,2, Qian Shao1,2 and Min Xu1,2
1Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China
2Shandong Academy of Medical Sciences, Jinan, China
3Changqing People’s Hospital, Jinan, China
Jianbin Li, email: [email protected]
Keywords: non-small cell lung cancer (NSCLC), four-dimensional computed tomography (4DCT), 18F-Fluorodeoxyglucose positron emission tomography CT (18F-FDG PET-CT), internal biological target volume (IBTV)
Received: November 18, 2016 Accepted: June 02, 2017 Published: July 01, 2017
Fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) and four-dimensional CT (4DCT) are used in several methods for defining the biological target volume (BTV) in primary non-small cell lung cancer (NSCLC). Disagreements between the assessments using these methodologies make the use of BTV for radiotherapy planning controversial. In this study, we compared existing methods with our proposed internal biological target volume (IBTV) metric, derived by combining internal target volume (ITV) and BTV metrics. We defined the IBTV from ITV (IBTVi) or BTV (IBTVb) based on ITV or BTV with symmetrical margin expansion. We detected large differences between IBTV, IBTVi and IBTVb (p < 0.001), but no difference between ITV and BTV. A margin expansion of about 13 mm was necessary for ITV or BTV to encompass > 95% IBTV. The conformity index correlated negatively with IBTV/ITV, IBTV/BTV, IBTVi/ITV, and IBTVb/BTV volume ratios (p < 0.05). VR also increased the margins of IBTVi and IBTVb. Indeed, IBTV was much smaller than IBTVi or IBTVb, suggesting that using IBTV for radiotherapy planning could improve treatment by minimizing the radiation exposure of healthy tissue and organs surrounding tumors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.